Full Suite of Cxbladder Tests Adopted by NZ Public Healthcare Provider Capital & Coast DHB
08th November 2018

Cancer diagnostics company, Pacific Edge (NZX: PEB), has entered into an agreement with one of New Zealand’s largest public healthcare providers, Capital & Coast District Health Board (CCDHB), to provide its suite of Cxbladder cancer diagnostic tests for the detection, management and monitoring of bladder cancer patients. Read More

Cxbladder Commercial Evaluation by Johns Hopkins Medicine
15th October 2018

Cancer diagnostics company, Pacific Edge, advises that Johns Hopkins Medicine has commenced their commercial evaluation of Cxbladder, the company’s non-invasive molecular diagnostic test for the detection and management of bladder cancer, with a number of urologists at the institution. Read More

Another New Zealand Public Healthcare Provider Signs Up to Cxbladder
14th August 2018

Cancer diagnostics company Pacific Edge (NZX: PEB) has received notification from Counties Manukau District Health Board (CMDHB) regarding adoption of the suite of Cxbladder cancer diagnostic tests for use across the clinical pathway. Read More

Pacific Edge Signs First Commercial Agreement in Singapore
01st February 2018

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has reached a commercial agreement with Raffles Diagnostica Pte Ltd to offer its suite of Cxbladder tests in Singapore. Read More